Full FDA hold de­rails clin­i­cal study of Ful­crum drug in a no good, very bad week for sick­le cell R&D

The roller-coast­er ride of highs and lows at Cam­bridge, MA-based Ful­crum Ther­a­peu­tics just took a sick­en­ing plunge.

Weeks af­ter us­ing some up­beat re­sults to set the stage for a $125 mil­lion raise — no easy feat in this mar­ket — the Ful­crum team got hit with a full clin­i­cal hold on one of their top drugs. And the news ripped up a chunk of mar­ket val­ue that sent shares $FULC tum­bling more than 50% Fri­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER